Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
12.17
-0.44 (-3.49%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Benitec Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
19
Market Cap
416.88M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| REGENXBIO | 170.44M |
| Assembly Biosciences | 72.30M |
| Invivyd | 53.43M |
| Prelude Therapeutics | 12.14M |
| PureTech Health | 6.39M |
| Neurogene | 925.00K |
BNTC News
- 1 day ago - Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting - GlobeNewsWire
- 7 weeks ago - Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD) - GlobeNewsWire
- 3 months ago - Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response - GlobeNewsWire
- 5 months ago - Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update - GlobeNewsWire
- 6 months ago - Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering - GlobeNewsWire
- 6 months ago - Benitec Biopharma Inc. Announces Proposed Public Offering - GlobeNewsWire
- 6 months ago - Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301 - GlobeNewsWire
- 6 months ago - Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy - GlobeNewsWire